Business Wire

AL-ADTRAN

23.2.2024 11:01:27 CET | Business Wire | Press release

Share
Vodafone Turkey deploys Adtran optical cesium solution in national timing network

Adtran today announced that Vodafone Turkey has deployed its Oscilloquartz optical cesium atomic clock technology to bring new levels of resilient timing to its nationwide network. Adtran’s first-to-market solution will deliver robust protection against disruptions to GNSS signals, enabling Turkey’s leading service provider to maintain uninterrupted, reliable connectivity even while it readies 5G services. By combining its existing Adtran Oscilloquartz core grandmaster clock devices with the new optical cesium atomic clock technology, Vodafone Turkey has an ePRTC+ solution that guarantees accurate network synchronization during any possible GNSS unavailability. Artıtel also played a key role in the deployment, facilitating logistics and supply management.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240222821658/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Vodafone Turkey is using Adtran’s optical cesium solution to bring new levels of resilient timing to its nationwide network (Photo: Business Wire)

“Our new solution injects outstanding reliability and precision into our national synchronization network. It’s a key step in our 5G strategy, enhancing service performance and equipping us to address emerging timing challenges. Now we can guarantee a seamless user experience as we provide more customers with access to data-intensive applications and uninterrupted high-quality video streaming,” said Yago Lopez, network director at Vodafone Turkey. “Threats to GNSS are multiplying, so we need to harness technology that bolsters the resilience of our entire timing network. We’ve also seen the impact that devastating natural disasters can have on GNSS accuracy and availability. That’s why Adtran’s Oscilloquartz ePRTC+ technology is so crucial. It safeguards synchronization input for our network and ensures it remains stable in the most challenging conditions.”

For enhanced redundancy, Vodafone Turkey is strategically deploying Adtran’s Oscilloquartz ePRTC+ across five different sites. Central to the solution are the Oscilloquartz OSA 3350 ePRC+, which utilizes optical pumping technology to achieve high-performance frequency stability, and Vodafone Turkey’s existing core grandmaster clocks, the OSA 5430 and OSA 5440. Along with the Oscilloquartz clock combiner, these components form the complete ePRTC+ system. Capable of maintaining 100 nanoseconds holdover for at least 45 days, and typically up to 55 days, it surpasses current ITU-T G.811.1 standards. The solution provides Vodafone Turkey with optimal stability, outperforming the lifespan of other high-performance magnetic cesium clocks. It also features a modular design, which includes a wide range of synchronization output interfaces and supports secured management capabilities, including SNMP – essential for efficient network management and security.

“With its deployment of our ePRTC+ system, Vodafone Turkey is introducing next-level timing resilience into its network. This helps ensure every customer has seamless and uninterrupted access to some of the fastest mobile services available,” commented Stuart Broome, GM of EMEA sales at Adtran. “Combining our grandmaster GNSS receivers with our ultra-accurate OSA 3350 ePRC+ ensures protection for Vodafone Turkey’s timing and synchronization operations with the industry’s longest holdover. It will help Vodafone Turkey set new benchmarks in network reliability and service quality.”

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

Published by
ADTRAN Holdings, Inc.
www.adtran.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240222821658/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye